Reader in Immune Regulation
Dr Amarnath leads a research laboratory at Newcastle University studying the role of the immune system in driving anti-tumour responses. Her laboratory is particularly interested in understanding how the immune system develops resistance to a specific class of immunotherapy drugs called checkpoint blockers.
Checkpoint inhibitor therapies has shown tremendous success in a fraction of patients with liver cancer but why others do not respond or develop resistance is unknown. Using murine models and primary patient samples, Dr. Amarnath’s laboratory aims to decipher how the immune system of cancer patients develop resistance to these drugs and what key biomarkers can identify a recalcitrant immune system in cancer.
These studies will enable us to stratify patient populations in a more efficient manner and enhance the efficacy of checkpoint inhibitor therapy.